• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

    6/20/24 8:22:52 AM ET
    $ASLN
    $ASNS
    $BILI
    $DXF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Telecommunications Equipment
    Telecommunications
    Get the next $ASLN alert in real time by email

    Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses.

    Vuzix shares jumped 15% to $1.53 in the pre-market trading session.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) rose 109.8% to $0.2497 in pre-market trading after jumping 19% on Tuesday.
    • Selina Hospitality PLC (NASDAQ:SLNA) gained 46.9% to $0.1024 in pre-market trading after declining 7% on Tuesday.
    • Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 44.5% to $4.12 in pre-market trading. Tempest will report new data from global randomized combination study of Amezalpat (TPST-1120) in first-line hepatocellular carcinoma on June 20.
    • Nexalin Technology, Inc. (NASDAQ:NXL) gained 27.8% to $1.33 in pre-market trading. Nexalin Technology shares jumped around 38% on Tuesday after the company was awarded a US patent on ‘Transcranial alternating current dynamic frequency stimulation (TACS) method for Alzheimers and Dementia.’
    • Presto Automation Inc. (NASDAQ:PRST) shares climbed 19.7% to $0.0880 in pre-market trading after falling around 5% on Tuesday.
    • Molecular Partners AG (NASDAQ:MOLN) shares rose 19.5% to $9.50 in pre-market trading after gaining 9% on Tuesday.
    • Griid Infrastructure Inc. (NASDAQ:GRDI) rose 17.7% to $0.6598 in pre-market trading after falling more than 10% on Tuesday.
    • ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) shares gained 14.7% to $0.3581 in pre-market trading after dipping 13% on Tuesday.
    • Bilibili Inc. (NASDAQ:BILI) shares climbed 8% to $17.47 in pre-market trading. On Tuesday, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price target.

    Losers

    • NLS Pharmaceutics AG (NASDAQ:NLSP) shares fell 22% to $0.2107 in pre-market trading after jumping 82% on Tuesday.
    • La Rosa Holdings Corp. (NASDAQ:LRHC) shares fell 17.2% to $1.48 in pre-market trading. La Rosa Holdings shares jumped 72% on Tuesday after the company entered a non-binding letter of intent to acquire a controlling interest in Red Door Title.
    • Kaival Brands Innovations Group, Inc (NASDAQ:KAVL) shares declined 15.5% to $3.80 in pre-market trading after gaining 8% on Tuesday.
    • Huize Holding Limited (NASDAQ:HUIZ) shares fell 15% to $0.85 in pre-market trading.
    • Actelis Networks, Inc. (NASDAQ:ASNS) fell 14.2% to $1.82 in pre-market trading. Actelis Networks shares jumped 84% on Tuesday after the company announced an agreement to serve as Carahsoft’s public sector distributor.
    • SRIVARU Holding Limited (NASDAQ:SVMH) shares fell 13.3% to $0.2160 in pre-market trading. SRIVARU, last week, announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16th.
    • Virios Therapeutics Inc (NASDAQ:VIRI) shares declined 12.1% to $0.22 in pre-market trading.
    • Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) shares dipped 9% to $2.66 in pre-market trading after dipping over 14% on Tuesday.
    • Dunxin Financial Holdings Limited (NASDAQ:DXF) shares fell 9.4% to $0.1950 in pre-market trading after dipping 17% on Tuesday.
    • Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell 6% to $5.96 in pre-market trading after the company rejected unsolicited takeover bids, citing undervaluation.

    Now Read This: Investor Sentiment Improves After S&P 500 Hits Another Record Close On Tuesday

    Get the next $ASLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASLN
    $ASNS
    $BILI
    $DXF

    CompanyDatePrice TargetRatingAnalyst
    Bilibili Inc.
    $BILI
    3/27/2026$27.00Neutral → Buy
    Citigroup
    Bilibili Inc.
    $BILI
    3/17/2026$35.00Neutral → Overweight
    Analyst
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Molecular Partners AG
    $MOLN
    1/27/2026$13.00Buy
    H.C. Wainwright
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Bilibili Inc.
    $BILI
    10/14/2025$36.03Outperform
    Macquarie
    Bilibili Inc.
    $BILI
    7/28/2025$24.00Overweight → Neutral
    Analyst
    More analyst ratings

    $ASLN
    $ASNS
    $BILI
    $DXF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bilibili upgraded by Citigroup with a new price target

    Citigroup upgraded Bilibili from Neutral to Buy and set a new price target of $27.00

    3/27/26 9:03:14 AM ET
    $BILI
    EDP Services
    Technology

    Bilibili upgraded by Analyst with a new price target

    Analyst upgraded Bilibili from Neutral to Overweight and set a new price target of $35.00

    3/17/26 12:27:13 PM ET
    $BILI
    EDP Services
    Technology

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $ASNS
    $BILI
    $DXF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Angel Matthew

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    3/25/26 5:32:36 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Tam Ronald

    3 - Huize Holding Ltd (0001778982) (Issuer)

    3/18/26 8:12:52 AM ET
    $HUIZ
    Specialty Insurers
    Finance

    SEC Form 3 filed by new insider Xiao Minghan

    3 - Huize Holding Ltd (0001778982) (Issuer)

    3/18/26 8:19:27 AM ET
    $HUIZ
    Specialty Insurers
    Finance

    $ASLN
    $ASNS
    $BILI
    $DXF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Huize Holding Limited Reports Unaudited Financial Results for the Second Half and Full Year 2025

    SHENZHEN, China, March 27, 2026 (GLOBE NEWSWIRE) -- Huize Holding Limited, ("Huize", the "Company" or "we") (NASDAQ:HUIZ), a leading insurance technology platform connecting consumers, insurance carriers, and distribution partners digitally through data-driven and AI-powered solutions in Asia, today announced its unaudited financial results for the second half and full year ended December 31, 2025. Full Year 2025 Financial and Operational Highlights Record-breaking insurance premiums: Both first year premiums ("FYP") and gross written premiums ("GWP") reached record highs of RMB4,630.8 million and RMB7,427.1 million in 2025, representing robust increases of 35.4% and 20.6% year-over-yea

    3/27/26 5:00:00 AM ET
    $HUIZ
    Specialty Insurers
    Finance

    Actelis Networks Secures Follow-On Order from Major North American Railway for Trackside Network Expansion Supporting Rail Safety Systems

    Sunnyvale, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid-deployment networking solutions for IoT and broadband applications, today announced it has received a follow-on order from a major North American railway operator to expand its trackside networking infrastructure supporting critical rail safety and control systems. This follow-on order builds on prior deployments and reflects the ongoing expansion of advanced rail safety and control systems across North American rail networks, where dependable communications infrastructure is a foundational requirement. The new order will support

    3/26/26 9:00:00 AM ET
    $ASNS
    Telecommunications Equipment
    Telecommunications

    Actelis Networks Announces Binding Term Sheet to Acquire Exaware, Entering AI Data Center Networking Market

    Transaction expected to mark Actelis' entry into the high-growth AI-driven data center networking market, leveraging Exaware's rapidly expanding footprint across data center environments Acquisition is designed to enable a unified, multi-layer, cyber-hardened networking platform spanning secure edge, aggregation, and data center connectivity for rapid, reliable and cost-effective deployment Subject to completion, the combined company will be positioned to capitalize on accelerating global demand for AI-driven bandwidth and network modernization SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyb

    3/24/26 9:10:00 AM ET
    $ASNS
    Telecommunications Equipment
    Telecommunications

    $ASLN
    $ASNS
    $BILI
    $DXF
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vanda Pharmaceuticals Inc.

    SCHEDULE 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

    3/27/26 1:55:31 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Huize Holding Limited

    6-K - Huize Holding Ltd (0001778982) (Filer)

    3/27/26 9:16:52 AM ET
    $HUIZ
    Specialty Insurers
    Finance

    SEC Form 6-K filed by Bilibili Inc.

    6-K - Bilibili Inc. (0001723690) (Filer)

    3/26/26 9:03:42 AM ET
    $BILI
    EDP Services
    Technology

    $ASLN
    $ASNS
    $BILI
    $DXF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $ASNS
    $BILI
    $DXF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $15,605 worth of Class A Shares (14,584 units at $1.07) and sold $9,121 worth of Class A Shares (8,368 units at $1.09), increasing direct ownership by 15% to 48,596 units (SEC Form 4)

    4 - La Rosa Holdings Corp. (0001879403) (Issuer)

    3/3/26 2:57:47 PM ET
    $LRHC
    Real Estate
    Finance

    Director Hanish Arnold C bought $3,740 worth of shares (5,000 units at $0.75) (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/24/25 5:08:13 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exec VP Finance, CFO Rosenblum Mark J bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 11,299% to 20,177 units (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/20/25 4:42:09 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $ASNS
    $BILI
    $DXF
    Leadership Updates

    Live Leadership Updates

    View All

    Deep Isolation Appoints Paula Whitten-Doolin as General Counsel

    BERKELEY, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Deep Isolation Nuclear, Inc. ("Deep Isolation" or the "Company"), a leading innovator in nuclear waste disposal technology, today announced the appointment of Paula Whitten-Doolin as the Company's General Counsel, effective immediately. Ms. Whitten-Doolin brings more than 15 years of experience in corporate and legal affairs to Deep Isolation, with deep expertise in the energy sector and advising publicly traded companies. Most recently, she served as General Counsel, Chief Administrative Officer and Chief Compliance Officer for Houston First Corporation, where she managed corporate governance, negotiated multimillion-dollar land deals,

    2/3/26 8:00:00 AM ET
    $VUZI
    Radio And Television Broadcasting And Communications Equipment
    Technology

    La Rosa Holdings Corp. Announces Appointment of Nicholas Adler as Chairman of the Board and Chairman of the Compensation Committee

    Celebration, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, today announced that the Company's Board of Directors (the "Board") has appointed Mr. Nicholas Adler as a member of the Board, effective December 29, 2025. Upon his appointment, Mr. Adler was also named Chairman of the Board, Chairman of the Compensation Committee, and a member of both the Audit Committee and the Nominating and Corporate Governance Committee. Additionally, on December 29, 2025, Mr. Siamack Alavi notified the Board of his resignation as a director of the Company, effective immediately. Mr. Alavi also stepped down from hi

    12/30/25 8:30:00 AM ET
    $FRGT
    $LRHC
    Professional Services
    Consumer Discretionary
    Real Estate
    Finance

    The AR Alliance Welcomes Vuzix as a New Member

    The AR Alliance, a division of SPIE focused on augmented reality (AR), proudly announces the addition of Vuzix® Corporation to its membership. Members of the AR Alliance reflect the global diversity and strength of the AR hardware development ecosystem, bringing expertise across foundational research, advanced optics, display technologies, intuitive user interfaces and spatial computing platforms. Their participation reinforces the Alliance's collaborative mission to accelerate innovation, support open standards, and unify the AR industry through concrete action and shared success. The AR Alliance provides a supportive and neutral environment for organizations of all sizes to take an acti

    11/25/25 9:05:00 AM ET
    $VUZI
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ASLN
    $ASNS
    $BILI
    $DXF
    Financials

    Live finance-specific insights

    View All

    Huize Holding Limited Reports Unaudited Financial Results for the Second Half and Full Year 2025

    SHENZHEN, China, March 27, 2026 (GLOBE NEWSWIRE) -- Huize Holding Limited, ("Huize", the "Company" or "we") (NASDAQ:HUIZ), a leading insurance technology platform connecting consumers, insurance carriers, and distribution partners digitally through data-driven and AI-powered solutions in Asia, today announced its unaudited financial results for the second half and full year ended December 31, 2025. Full Year 2025 Financial and Operational Highlights Record-breaking insurance premiums: Both first year premiums ("FYP") and gross written premiums ("GWP") reached record highs of RMB4,630.8 million and RMB7,427.1 million in 2025, representing robust increases of 35.4% and 20.6% year-over-yea

    3/27/26 5:00:00 AM ET
    $HUIZ
    Specialty Insurers
    Finance

    Huize Holding Limited to Report Second Half and Full Year 2025 Financial Results on March 27, 2026

    SHENZHEN, China, March 17, 2026 (GLOBE NEWSWIRE) -- Huize Holding Limited, ("Huize", the "Company") (NASDAQ:HUIZ), a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data-driven and AI-powered solutions in Asia, today announced that it plans to release its second half and full year 2025 unaudited financial results before the U.S. market opens on Friday, March 27, 2026. The Company's management team will hold an earnings conference call at 8:00 A.M. Eastern Daylight Time on Friday, March 27, 2026 (8:00 P.M. Beijing/Hong Kong Time on Friday, March 27, 2026). Details of the conference call are as follows: Event Title:

    3/17/26 6:00:00 AM ET
    $HUIZ
    Specialty Insurers
    Finance

    Vuzix Reports 2025 Financial Results and Positions Waveguide and OEM Businesses for Next Phase of Smart Glasses Growth

    ROCHESTER, N.Y., March 12, 2026 /CNW/ -- Vuzix® Corporation (NASDAQ:VUZI) ("Vuzix" or the "Company"), a leading supplier of AI-driven smart glasses, waveguides and Augmented Reality (AR) technologies, today reported its fourth quarter and full year financial results for the year ended December 31, 2025. "In 2025, we made meaningful progress in strengthening the foundation of Vuzix. We delivered modest revenue growth in products and engineering services, reduced operating cash usage by approximately $5.0 million, and achieved important milestones across our OEM and waveguide init

    3/12/26 4:25:00 PM ET
    $VUZI
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ASLN
    $ASNS
    $BILI
    $DXF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Kaival Brands Innovations Group Inc.

    SC 13D/A - Kaival Brands Innovations Group, Inc. (0001762239) (Subject)

    12/12/24 7:22:30 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by NLS Pharmaceutics Ltd.

    SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

    11/21/24 4:01:13 PM ET
    $NLSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NLS Pharmaceutics Ltd.

    SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

    11/14/24 7:27:23 PM ET
    $NLSP
    Biotechnology: Pharmaceutical Preparations
    Health Care